Climb Bio Inc (CLYM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Climb Bio Inc (CLYM) has a cash flow conversion efficiency ratio of -0.044x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.55 Million) by net assets ($239.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Climb Bio Inc for the company's overall valuation and market capitalisation.
Climb Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Climb Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Climb Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Climb Bio Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Climb Bio Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thunder Tiger Corp
TW:8033
|
-0.014x |
|
United Overseas Australia Ltd
AU:UOS
|
0.030x |
|
Si-Bone Inc
NASDAQ:SIBN
|
0.004x |
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
0.006x |
|
Akso Health Group ADR
NASDAQ:AHG
|
0.015x |
|
Jiangsu Nanfang Bearing Co Ltd
SHE:002553
|
0.029x |
|
Standard Foods Corp
TW:1227
|
0.063x |
|
PMB Technology Bhd
KLSE:7172
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Climb Bio Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025. View Climb Bio Inc (CLYM) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.47 Million | $-54.36 Million | -0.339x | -361.18% |
| 2024-12-31 | $211.88 Million | $-15.56 Million | -0.073x | +61.63% |
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more